Benefit Expense Ratio
 |
Definition of 'Benefit Expense Ratio'An operating metric used in the health insurance industry computed by dividing a company's costs associated with providing health services by the revenues from member premiums. Because of the large dollar values involved, a single percentage change in the benefit expense ratio can significantly impact the corporation's net income. Also called medical loss ratio or health benefit ratio. |
 |
Investopedia explains 'Benefit Expense Ratio'The benefit expense ratio compares a health insurer's expenses for providing health care with the revenues it receives. General insurance providers would want to minimize this ratio as it would indicate an increase in top line growth relative to expenses.In 2010, the Obama administration issued regulations regarding the proportion of premium dollars health insurers spend on patient care relative to administrative expenses. The regulation specifies targets of 80% for small business plans and 85% for large-company plans. |
Related Definitions
Articles Of Interest
-
Investing In Health Insurance Companies
Health insurance companies work a little differently than most companies. Here's what you need to know as an investor. -
Valeant Eyes Bausch & Lomb
Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was buying Bausch & Lomb for $8.7 billion making it a global leader in ... -
Medtronic Still Reporting Weak Growth, But A Relatively Rare Bargain
Medtronic continues to suffer with weak core markets, but business seems to be getting slowly better and valuation is not demanding -
Roche, Reloaded
Roche has one of the best long-term growth profiles in the Big Pharma space -
Elan Continues To Make Baffling Strategic Decision
Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders -
After A Big Rally, Pfizer Might Need Some Rest
A big rally has brought Pfizer back to fair value. -
Adasuve Deal Is Very Good For Alexza, But What About Teva?
Teva's partnership with Alexza looks like an expensive gamble. -
Recent Financials May Not Be Entirely Fair To Hologic
Macro pressures are outweighing solid internal progress at Hologic. -
Amgen Chased By The Bubble
Amgen really needs the pipeline to come through to support this valuation. -
Teva Still Too Cheap, But Still Too Uncertain
Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
Free Annual Reports
